ABT-089 (Pozanicline) — Safety, Research, Risks & Legal Status

Not medical advice. ABT-089 (Pozanicline) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Pozanicline; ABT-089; CAS 161417-03-4 (free base)
Category	Research Chemical
Drug class	Selective alpha-4-beta-2 neuronal nicotinic acetylcholine receptor (nAChR) partial agonist
Developer	Abbott Laboratories
CAS (free base)	161417-03-4
Binding affinity	Ki approximately 17 nM at rat brain alpha-4-beta-2 nAChR
Highest development stage	Phase 2 (multiple indications; all discontinued)
Reason for discontinuation	Inconsistent and insufficient efficacy across ADHD (pediatric and adult), Alzheimer's disease, and smoking cessation trials; not a primary safety concern
US legal status	Investigational only in the United States. ABT-089 was never submitted for FDA NDA or BLA approval and carries no ATC code. It is not approved for any indication domestically or internationally. Development has been discontinued. It is not a licensed pharmaceutical, dietary supplement, or over-the-counter product. Possession and use outside of a formal research context occupies a regulatory gray zone; it is not a controlled substance under the CSA but is also not lawfully marketed for human consumption.

What is ABT-089 (Pozanicline)?

ABT-089 (pozanicline) is a selective partial agonist at the alpha-4-beta-2 (α4β2) subtype of neuronal nicotinic acetylcholine receptors (nAChRs), developed by Abbott Laboratories as an investigational drug. It was evaluated across multiple Phase 2 clinical trials for ADHD (adults and children), mild-to-moderate Alzheimer's disease, and smoking cessation, but failed to demonstrate consistent efficacy in larger trials and development was discontinued. It was never approved by any regulatory agency.

How it works

Pozanicline binds with high affinity (Ki approximately 17 nM) to rat brain α4β2 nAChRs and shows additional activity at the α6β2 subtype. As a partial agonist rather than a full agonist, it produces submaximal receptor activation. This partial agonism is hypothesized to modulate acetylcholine and dopamine neurotransmission in a more controlled manner than full agonists, which formed the rationale for investigating cognitive and attentional effects. The precise mechanism by which partial α4β2 agonism might translate to cognitive benefit in humans remains incompletely characterized, and the clinical trial record does not provide strong validation of the pharmacological hypothesis in the populations studied.

Background & history

ABT-089 was developed by Abbott Laboratories as part of a program targeting nicotinic receptor subtypes for cognitive and psychiatric indications. Early animal studies showed effects on ADHD-like symptoms, cognitive performance, and addiction-related behaviors. An early crossover pilot study in adult ADHD patients (approximately 2005) reported favorable signals at 40 mg once and twice daily dosing. Based on this, the compound advanced to larger trials. Subsequent Phase 2 trials in pediatric ADHD (two large randomized studies) failed on primary outcomes. A Phase 2 trial in mild-to-moderate Alzheimer's disease (NCT00555204) was completed but produced insufficient efficacy signals. A smoking cessation trial (NCT01756053) was terminated early after a pre-specified interim futility analysis. One adult ADHD trial was also prematurely halted pending additional preclinical safety data, though the specific safety concern was not detailed in the public literature. Abbott discontinued development; discontinuation is attributed to inconsistent efficacy across indications and populations rather than a safety crisis.

What the research says

The human evidence base for pozanicline is limited and largely negative. An early crossover pilot in adults with ADHD suggested efficacy at 40 mg once or twice daily, but a subsequent randomized pilot study (2008) found no statistically significant treatment effect at 40 mg or 80 mg once daily versus placebo. Two large randomized controlled trials in children with ADHD failed to meet primary efficacy endpoints; adverse event profiles were comparable to placebo. The Phase 2 Alzheimer's disease trial (NCT00555204) was completed but published results reflect modest or insufficient signals. The smoking cessation trial (NCT01756053) was terminated due to futility. Collectively, the clinical record does not support efficacy for any of the evaluated indications. Animal data provided the original mechanistic rationale but did not predict clinical outcomes reliably.

Reported effects

Partial agonism at alpha-4-beta-2 neuronal nicotinic acetylcholine receptors - the proposed basis for any cognitive or attentional effects (mechanism only; clinical benefit not established)
Modulation of acetylcholine and dopamine release via nAChR partial agonism (preclinical pharmacology; translation to humans unconfirmed)
No statistically significant improvement in ADHD symptoms demonstrated in large pediatric randomized controlled trials
No significant difference from placebo in a randomized adult ADHD pilot study at 40 mg and 80 mg once daily
Insufficient efficacy signal in Phase 2 Alzheimer's disease trial
Smoking cessation trial terminated early for futility at interim analysis

Dosing & administration (informational)

Published Phase 2 trial protocols used 40 mg once daily, 40 mg twice daily, and 80 mg once daily oral dosing in adult ADHD populations. Pediatric and Alzheimer's disease trial dosing parameters are not fully disclosed in public summaries. These ranges appear solely as literature context from clinical trial records. This is not a dosing recommendation or protocol. No safe or effective dose has been established for any indication given the negative efficacy findings. Consult a licensed clinician before considering any investigational compound.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Generally well-tolerated in Phase 2 trials; adverse event rates were statistically similar to placebo in pediatric ADHD studies
Most commonly reported events in trials: nasopharyngitis, upper respiratory infection, somnolence
No major cardiovascular, hepatotoxic, or psychiatric safety signals identified in public trial records
One adult trial was prematurely terminated pending additional preclinical safety data; the specific concern was not disclosed in public literature - this represents an unresolved uncertainty
Safety profile in long-term or real-world use is unknown given discontinued development and absence of post-market data
No human safety data exist outside the controlled trial setting; extrapolation beyond that context is not supported by evidence

Drug & supplement interactions

N
o
f
o
r
m
a
l
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
a
p
p
e
a
r
i
n
t
h
e
p
u
b
l
i
c
l
i
t
e
r
a
t
u
r
e
f
o
r
p
o
z
a
n
i
c
l
i
n
e
.
A
s
a
n
n
A
C
h
R
p
a
r
t
i
a
l
a
g
o
n
i
s
t
,
t
h
e
o
r
e
t
i
c
a
l
i
n
t
e
r
a
c
t
i
o
n
s
w
o
u
l
d
i
n
c
l
u
d
e
a
d
d
i
t
i
v
e
o
r
c
o
m
p
e
t
i
t
i
v
e
e
f
f
e
c
t
s
w
i
t
h
o
t
h
e
r
n
i
c
o
t
i
n
i
c
a
g
e
n
t
s
(
v
a
r
e
n
i
c
l
i
n
e
,
n
i
c
o
t
i
n
e
r
e
p
l
a
c
e
m
e
n
t
)
,
a
n
d
p
o
t
e
n
t
i
a
l
m
o
d
u
l
a
t
i
o
n
o
f
d
o
p
a
m
i
n
e
r
g
i
c
c
i
r
c
u
i
t
s
r
e
l
e
v
a
n
t
t
o
s
t
i
m
u
l
a
n
t
m
e
d
i
c
a
t
i
o
n
s
o
r
d
o
p
a
m
i
n
e
-
a
c
t
i
v
e
d
r
u
g
s
.
C
y
t
o
c
h
r
o
m
e
P
4
5
0
i
n
t
e
r
a
c
t
i
o
n
p
r
o
f
i
l
e
i
s
n
o
t
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
a
v
a
i
l
a
b
l
e
p
u
b
l
i
c
d
a
t
a
.
T
h
i
s
a
r
e
a
i
s
e
s
s
e
n
t
i
a
l
l
y
u
n
s
t
u
d
i
e
d
.

Who should avoid it

Concurrent use with nicotinic agonists or antagonists (varenicline, nicotine, mecamylamine) - additive or competitive receptor effects are theoretically possible but unstudied
Use in pediatric populations - two large RCTs showed no efficacy and development was abandoned
Use for any indication the compound was tested for - no indication achieved demonstrated efficacy in Phase 2
Sourcing from unverified chemical suppliers - no pharmaceutical-grade product exists and purity cannot be assumed

How it is commonly combined

No evidence base exists for combining pozanicline with other compounds. The compound's development was discontinued, and no human research into combination regimens has been conducted or published. Any stacking rationale would be purely speculative.

Legal & regulatory. Investigational only in the United States. ABT-089 was never submitted for FDA NDA or BLA approval and carries no ATC code. It is not approved for any indication domestically or internationally. Development has been discontinued. It is not a licensed pharmaceutical, dietary supplement, or over-the-counter product. Possession and use outside of a formal research context occupies a regulatory gray zone; it is not a controlled substance under the CSA but is also not lawfully marketed for human consumption.

Quality & harm reduction

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find ABT-089 (Pozanicline) →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Was ABT-089 ever approved for any medical use?

No. ABT-089/pozanicline was never approved by the FDA or any other regulatory body for any indication. It remained investigational throughout its development and was discontinued after Phase 2 trials produced insufficient efficacy data.

Did it show any benefit in clinical trials?

An early crossover pilot study in adults with ADHD suggested favorable signals at 40 mg, but a subsequent randomized pilot study found no statistically significant effect versus placebo. Two large randomized trials in children with ADHD failed on primary endpoints. The Alzheimer's disease Phase 2 trial produced insufficient efficacy signals, and the smoking cessation trial was terminated early for futility. The overall clinical record is negative.

Why was development discontinued - was it unsafe?

Discontinuation appears driven primarily by insufficient and inconsistent efficacy rather than a safety crisis. Adverse event profiles in pediatric and adult trials were statistically comparable to placebo. One adult trial was terminated pending additional preclinical safety data, though the specific concern was not disclosed publicly, representing an unresolved gap in the public record.

What is the recommended dose for cognitive enhancement?

There is no established safe or effective dose for any indication, including cognitive enhancement, which was never a formal trial endpoint. Providing a dosing protocol would not be appropriate. Anyone considering an investigational compound should consult a licensed clinician.

Is ABT-089 legally obtainable in the United States?

It is not a scheduled controlled substance under the CSA, but it is also not an approved pharmaceutical, supplement, or lawfully marketed product for human use. It occupies a regulatory gray zone. No pharmaceutical-grade supply chain exists given discontinued development.

How does it differ from varenicline (Chantix) or nicotine?

All three act at nicotinic acetylcholine receptors, but they differ in receptor subtype selectivity and degree of agonism. Varenicline is a partial agonist approved for smoking cessation; nicotine is a full agonist. ABT-089 was selective for alpha-4-beta-2 with partial agonism intended to minimize side effects associated with full agonists, but unlike varenicline it failed to demonstrate efficacy in its target indications and was abandoned.

References & further reading

PubMed: ABT-089 pozanicline randomized pilot study adults ADHD efficacy safety
PubMed: ABT-089 pediatric ADHD efficacy safety randomized controlled trial
ClinicalTrials.gov: NCT00555204 (ABT-089 Alzheimer's disease Phase 2)
ClinicalTrials.gov: NCT00554385 (ABT-089 pediatric ADHD safety tolerability)
ClinicalTrials.gov: NCT01756053 (ABT-089 smoking cessation, terminated futility)